Evotec has reached a final agreement to acquire 100% of the capital of Italian-based cell technology company Rigenerand for $ 24.7 million (€ 23 million).
Founded in 2009 as a spin-off between the University of Modena and Reggio Emilia, Rigenerand focuses on the production of cGMP for cell therapy.
The company operates a certified production facility that integrates cGMP manufacturing with research and development (R & D) and QC labs, as well as development labs.
Called the “cell factory,” the factory consists of a well-equipped clean room for creating complex cell-based therapies.
Located in Medolla, Italy, the site consists of 1,200 m² of high-tech production space and can be expanded further.
Through the acquisition, Evotec will add a team of experts in cell therapy cGMP manufacturing.
The agreement adds Evotec’s cell therapy platform, EVOcells, to the cGMP manufacturing site.
In this area, we need to integrate the discovery and development of new therapies, along with our in-house expertise in GMP production.
Although the revenue contribution may not be significant in the early stages, Rigenerand’s production expertise enhances Evotec’s ability to enter new, integrated collaborations within the field of cell therapy, along with Evotec’s R & D capabilities. increase.
Dr. Werner Lanthaler, CEO of Evotec, said:
“Originally from our leading iPSC platform, Evotec’s EVOcells platform enables us to deliver innovative cell therapies to patients from the beginning.
“The acquisition of Rigenerand adds manufacturing capabilities and expertise to the EVOcells platform.”
The company has developed EVOcells as an integrated and versatile platform for discovering, developing and producing cell therapies.
Evotec’s EVOcells project portfolio includes immuno-oncology, metabolic disorders, cardiac repair, and exosome-based therapies.
The latest developments will take place after Evotec and Sernova have entered into an exclusive global strategic partnership to develop cell therapies for insulin-dependent diabetes.
The range of cell and gene therapies related to pharmaceutical technology is supported by Cytiva..
Editorial content is created independently and Highest standard Of the integrity of journalism. Topic sponsors are not involved in creating edited content.
Secure a bench-to-bedside cell therapy supply chain
The development of cell therapies is changing health care and bringing new hope to thousands of patients around the world. However, the vein-to-venous workflow of these therapies is not without challenges, many of which increase as we scale up to treat more patients. Download this free guide from Cytiva to learn about the challenges and risks associated with the cryogenic supply chain for cell therapy and how to best mitigate supply chain disruption.
By Cytiva Thematic
[無料のホワイトペーパーをダウンロード]By clicking the button, you accept the terms of use and acknowledge that your data will be used as described in the Cytiva Thematic Privacy Policy. By downloading this white paper, we acknowledge that we may share information with our white paper partners / sponsors. Anyone who may contact you directly with information about the product or service.
For more information about our services, how we use, process and share your personal data, please see our Privacy Policy. This includes information about your rights to your personal data and how to unsubscribe from future marketing communications. Our service is intended for corporate subscribers and ensures that the email address sent is the corporate email address.
Thank you very much.Please check your email to download the white paper.